[8-K] NRX Pharmaceuticals, Inc. Reports Material Event
NRx Pharmaceuticals (NRXP) reported that its subsidiary, HOPE Therapeutics, completed the acquisition of a strategic minority interest in Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates on October 17, 2025. The deal was executed under a Membership Interest Purchase Agreement with customary representations, warranties, indemnification, and post‑closing adjustments.
In connection with the transaction, Dr. Rebecca Cohen was appointed Medical Director of HOPE Therapeutics, with employment terms that include financial incentives to establish and grow new sites of care owned or operated by HOPE Therapeutics. The company also furnished a related press release as Exhibit 99.1.
NRx Pharmaceuticals (NRXP) ha riferito che la sua controllata, HOPE Therapeutics, ha completato l'acquisizione di una partecipazione minoritaria strategica in Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates il 17 ottobre 2025. L'accordo è stato eseguito ai sensi di un Membership Interest Purchase Agreement con le consuete rappresentazioni, garanzie, indennizzo e adeguamenti post‑chiusura.
In relazione alla transazione, Dr. Rebecca Cohen è stata nominata Direttore Medico di HOPE Therapeutics, con termini di impiego che includono incentivi finanziari per stabilire e far crescere nuove sedi di assistenza gestite o possedute da HOPE Therapeutics. L'azienda ha inoltre fornito un comunicato stampa correlato come Exhibit 99.1.
NRx Pharmaceuticals (NRXP) informó que su subsidiaria, HOPE Therapeutics, completó la adquisición de una participación minoritaria estratégica en Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates el 17 de octubre de 2025. El acuerdo se ejecutó bajo un Membership Interest Purchase Agreement con las representaciones, garantías, indemnización y ajustes post‑cierre habituales.
En relación con la transacción, Dra. Rebecca Cohen fue designada Directora Médica de HOPE Therapeutics, con términos de empleo que incluyen incentivos financieros para establecer y hacer crecer nuevos sitios de atención pertenecientes u operados por HOPE Therapeutics. La empresa también adjuntó un comunicado de prensa relacionado como Exhibit 99.1.
NRx Pharmaceuticals (NRXP)는 자회사 HOPE Therapeutics가 2025년 10월 17일 Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates의 전략적 소수 지분을 인수하는 것을 완료했다고 발표했습니다. 거래는 일반적인 진술, 보증, 면책 및 종결 후 조정을 포함하는 구성원 지분 매매 계약(Membership Interest Purchase Agreement)에 따라 체결되었습니다.
거래와 관련하여 Dr. Rebecca Cohen은 HOPE Therapeutics의 의료 이사로 임명되었으며, 고용 조건에는 HOPE Therapeutics가 소유하거나 운영하는 새로운 진료 장소를 설립하고 성장시키기 위한 재정적 인센티브가 포함되어 있습니다. 회사는 또한 Exhibit 99.1로 관련 보도자료를 제시했습니다.
NRx Pharmaceuticals (NRXP) a annoncé que sa filiale, HOPE Therapeutics, a conclu l'acquisition d'une participation minoritaire stratégique dans Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates le 17 octobre 2025. L'accord a été conclu dans le cadre d'un Membership Interest Purchase Agreement comprenant les représentations, garanties, indemnisation et les ajustements post‑clôture habituels.
Dans le cadre de la transaction, Dr. Rebecca Cohen a été nommée Directrice Médicale de HOPE Therapeutics, avec des conditions d'emploi incluant des incitations financières pour établir et développer de nouveaux sites de soins possédés ou exploités par HOPE Therapeutics. La société a également fourni un communiqué de presse connexe en tant qu'Exhibit 99.1.
NRx Pharmaceuticals (NRXP) berichtete, dass seine Tochtergesellschaft HOPE Therapeutics am 17. Oktober 2025 eine strategische Minderheitsbeteiligung an Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates erworben hat. Die Transaktion wurde im Rahmen eines Membership Interest Purchase Agreement mit den üblichen Zusicherungen, Gewährleistungen, Entschädigungen und post‑Closing‑Anpassungen durchgeführt.
Im Zusammenhang mit der Transaktion wurde Dr. Rebecca Cohen zur Medical Director von HOPE Therapeutics ernannt, mit Beschäftigungsbedingungen, die finanzielle Anreize zur Errichtung und zum Wachstum neuer Versorgungsstandorte umfassen, die HOPE Therapeutics gehört oder betrieben werden. Das Unternehmen legte zudem eine dazugehörige Pressemitteilung als Exhibit 99.1 vor.
NRx Pharmaceuticals (NRXP) أعلنت أن شركتها الفرعية HOPE Therapeutics أكملت الاستحواذ على حصة أقلية استراتيجية في Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates في 17 أكتوبر 2025. تم تنفيذ الصفقة بموجب اتفاقية شراء حصة أعضاء (Membership Interest Purchase Agreement) مع التمثيلات والضمانات والتعويضات والتعديلات اللاحقة الإغلاق المعتادة.
وبموجب الصفقة، تم تعيين الدكتورة ريبيكا كوهين كمدير طبي لـ HOPE Therapeutics، مع شروط توظيف تتضمن حوافز مالية لإنشاء ونمو مواقع رعاية جديدة مملوكة أو مُدارة من قبل HOPE Therapeutics. كما قدمت الشركة بياناً صحفياً ذا صلة كـ Exhibit 99.1.
NRx Pharmaceuticals (NRXP)宣布，其子公司 HOPE Therapeutics 已于 2025 年 10 月 17 日完成对 Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates 的战略性少数股权收购。该交易根据包含惯常的陈述、保证、赔偿和收盘后调整的成员权益购买协议（Membership Interest Purchase Agreement）执行。
在交易相关事项中，Rebecca Cohen 医师 被任命为 HOPE Therapeutics 的医疗总监，雇佣条款包括为建立和扩大 HOPE Therapeutics 拥有或运营的新护理点而设立的财政激励。公司还将相关的新闻稿作为 Exhibit 99.1 提供。
- None.
- None.
Insights
Strategic minority stake adds clinical leadership and expansion focus.
NRx Pharmaceuticals, via HOPE Therapeutics, completed a minority investment in Cohen & Associates, aligning capital with clinical expertise. Minority stakes typically seek operational collaboration without assuming full control, which can limit risk while enabling strategic access.
Appointing Dr. Rebecca Cohen as Medical Director ties leadership to execution, with incentives directed at building new HOPE-owned or operated care sites. Execution will hinge on site rollout pace and integration quality with existing HOPE operations.
The included purchase agreement terms—customary reps, warranties, indemnification, and post-closing adjustments—are standard for private healthcare deals and frame ongoing obligations. Subsequent disclosures may detail performance outcomes tied to the incentivized site expansion.
NRx Pharmaceuticals (NRXP) ha riferito che la sua controllata, HOPE Therapeutics, ha completato l'acquisizione di una partecipazione minoritaria strategica in Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates il 17 ottobre 2025. L'accordo è stato eseguito ai sensi di un Membership Interest Purchase Agreement con le consuete rappresentazioni, garanzie, indennizzo e adeguamenti post‑chiusura.
In relazione alla transazione, Dr. Rebecca Cohen è stata nominata Direttore Medico di HOPE Therapeutics, con termini di impiego che includono incentivi finanziari per stabilire e far crescere nuove sedi di assistenza gestite o possedute da HOPE Therapeutics. L'azienda ha inoltre fornito un comunicato stampa correlato come Exhibit 99.1.
NRx Pharmaceuticals (NRXP) informó que su subsidiaria, HOPE Therapeutics, completó la adquisición de una participación minoritaria estratégica en Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates el 17 de octubre de 2025. El acuerdo se ejecutó bajo un Membership Interest Purchase Agreement con las representaciones, garantías, indemnización y ajustes post‑cierre habituales.
En relación con la transacción, Dra. Rebecca Cohen fue designada Directora Médica de HOPE Therapeutics, con términos de empleo que incluyen incentivos financieros para establecer y hacer crecer nuevos sitios de atención pertenecientes u operados por HOPE Therapeutics. La empresa también adjuntó un comunicado de prensa relacionado como Exhibit 99.1.
NRx Pharmaceuticals (NRXP)는 자회사 HOPE Therapeutics가 2025년 10월 17일 Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates의 전략적 소수 지분을 인수하는 것을 완료했다고 발표했습니다. 거래는 일반적인 진술, 보증, 면책 및 종결 후 조정을 포함하는 구성원 지분 매매 계약(Membership Interest Purchase Agreement)에 따라 체결되었습니다.
거래와 관련하여 Dr. Rebecca Cohen은 HOPE Therapeutics의 의료 이사로 임명되었으며, 고용 조건에는 HOPE Therapeutics가 소유하거나 운영하는 새로운 진료 장소를 설립하고 성장시키기 위한 재정적 인센티브가 포함되어 있습니다. 회사는 또한 Exhibit 99.1로 관련 보도자료를 제시했습니다.
NRx Pharmaceuticals (NRXP) a annoncé que sa filiale, HOPE Therapeutics, a conclu l'acquisition d'une participation minoritaire stratégique dans Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates le 17 octobre 2025. L'accord a été conclu dans le cadre d'un Membership Interest Purchase Agreement comprenant les représentations, garanties, indemnisation et les ajustements post‑clôture habituels.
Dans le cadre de la transaction, Dr. Rebecca Cohen a été nommée Directrice Médicale de HOPE Therapeutics, avec des conditions d'emploi incluant des incitations financières pour établir et développer de nouveaux sites de soins possédés ou exploités par HOPE Therapeutics. La société a également fourni un communiqué de presse connexe en tant qu'Exhibit 99.1.
NRx Pharmaceuticals (NRXP) berichtete, dass seine Tochtergesellschaft HOPE Therapeutics am 17. Oktober 2025 eine strategische Minderheitsbeteiligung an Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates erworben hat. Die Transaktion wurde im Rahmen eines Membership Interest Purchase Agreement mit den üblichen Zusicherungen, Gewährleistungen, Entschädigungen und post‑Closing‑Anpassungen durchgeführt.
Im Zusammenhang mit der Transaktion wurde Dr. Rebecca Cohen zur Medical Director von HOPE Therapeutics ernannt, mit Beschäftigungsbedingungen, die finanzielle Anreize zur Errichtung und zum Wachstum neuer Versorgungsstandorte umfassen, die HOPE Therapeutics gehört oder betrieben werden. Das Unternehmen legte zudem eine dazugehörige Pressemitteilung als Exhibit 99.1 vor.
